• Publications
  • Influence
Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
M2-like TAM dual-targeting nanoparticles (M2NPs), whose structure and function were controlled by α-peptide (a scavenger receptor B type 1 (SR-B1) targeting peptide) linked with M2pep (an M2 macrophage binding peptide), provide a potential strategy of molecular-targeted cancer immunotherapy for clinical application.
High-order photobleaching of green fluorescent protein inside live cells in two-photon excitation microscopy.
The results suggest that in applications where two-photon imaging of GFP is used to study dynamic molecular process, photobleaching may ruin the Imaging results and attention should be paid in interpreting the imaging results.
Redox ratio of mitochondria as an indicator for the response of photodynamic therapy.
The effect of photodynamic therapy (PDT) treatment on the metabolic state of tumor mitochondria is investigated by imaging of tumor redox status and the redox ratio is a sensitive indicator for providing reliable and informative measurements of PDT-induced tissue damage.
mBeRFP, an Improved Large Stokes Shift Red Fluorescent Protein
The generation of a monomeric large Stokes shift (LSS) red fluorescent protein, mBeRFP, with excitation and emission peaks at 446 and 615 nm, appears to be particularly useful for cellular imaging applications.
Biomimetic nanocarrier for direct cytosolic drug delivery.
The ability to transport a large quantity of drug molecules into cytosolic compartments of cancer cells has powerful implications in modern molecular therapeutics because the sites of action of the drugs are often cytosol organelles.
Pyropheophorbide 2-deoxyglucosamide: a new photosensitizer targeting glucose transporters.
Preliminary confocal microscopy studies suggest that Pyro-2DG is delivered and trapped in tumor cells via the GLUT/hexokinase pathway and therefore is useful both as a tumor-targeted NIR fluorescence imaging probe and as a PDT agent for the destruction of cancer.
Lipid-based nanoparticles in the systemic delivery of siRNA.
RNAi therapeutics are believed to be the future of personalized medicine and have shown promise in early clinical trials. However, many physiological barriers exist in the systemic delivery of siRNAs
HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting.
By adding targeting ligands to nanoparticles that mimic high-density lipoprotein (HDL), tumor-targeted sub-30-nm peptide-lipid nanocarriers are created with controllable size, cargo loading, and shielding properties.